Your Management Plan is Appropriate and Complete
Your clinical approach—omeprazole for 2 weeks, ondansetron for symptom control, and discharge with return precautions—is appropriate for this low-risk Mallory-Weiss tear, and no additional therapy or investigation is required at this time.
Clinical Reasoning
Why This Patient is Low-Risk
This 19-year-old presents with classic features of a self-limited Mallory-Weiss tear:
- Minimal hematemesis (less than a quarter-sized amount)
- Symptom improvement after initial event
- Hemodynamically stable with normal physical exam
- No subcutaneous air (ruling out esophageal perforation)
- Current mild xiphoid tenderness that is reproducible (likely musculoskeletal from retching)
The most recent Canadian guideline 1 specifically addresses Mallory-Weiss tears and recommends against endoscopic hemostatic therapy for nonbleeding MWTs with visible vessels, adherent clots, flat pigmented spots, or clean-based ulcers. Your patient, who is 2 days post-event and clinically improving, clearly falls into this low-risk category.
Evidence Supporting Conservative Management
Most Mallory-Weiss tears are self-limiting. Research consistently shows that 37-80% of patients require no blood transfusions 2, and the majority stop bleeding spontaneously 3, 4, 5. A large German cohort of nearly 60,000 cases found that only 13.7% required any endoscopic intervention 6, and surgical intervention was needed in only 0.1% of cases.
Patients without active bleeding at endoscopy have low rebleeding risk 7. The key risk factors for rebleeding include:
- Active bleeding at endoscopy
- Coagulopathy or bleeding diathesis
- Portal hypertension
- Hemodynamic instability at presentation
Your patient has none of these risk factors.
Your Medication Choices
Omeprazole: While the evidence for PPIs in Mallory-Weiss tears specifically is limited, the 2003 consensus guidelines 8 support PPI use in nonvariceal upper GI bleeding. The rationale is sound—acid suppression promotes mucosal healing. Your 2-week course is reasonable and safe 9.
Ondansetron: Appropriate for symptom control to prevent further vomiting and retching that could re-injure the healing mucosa. Be aware of QT prolongation risk 10, though this is minimal in a young, healthy patient without electrolyte abnormalities or cardiac disease.
What You DON'T Need
Endoscopy is not indicated in this stable, improving patient. The 2003 guidelines 8 note that patients with Mallory-Weiss tears and clean-based lesions can be discharged immediately after stabilization. Your patient is already 2 days out and improving—endoscopy would be low-yield and unnecessarily invasive.
No need for:
- H. pylori testing (this is for peptic ulcer disease, not Mallory-Weiss tears) 8
- Routine blood work if she's clinically stable
- Admission for observation
- Dietary restrictions beyond what's comfortable for the patient
Critical Return Precautions
Ensure she understands to return immediately for:
- Recurrent hematemesis (especially if more than the initial amount)
- Melena or hematochezia (suggesting ongoing bleeding)
- Lightheadedness, syncope, or palpitations (hemodynamic compromise)
- Severe chest or epigastric pain (concern for deeper injury)
- Fever or dysphagia (infection or perforation, though extremely unlikely at this point)
Common Pitfalls to Avoid
Don't over-investigate stable patients. The natural history of Mallory-Weiss tears is benign in the vast majority of cases 2, 6. Aggressive workup in low-risk patients leads to unnecessary procedures, costs, and patient anxiety.
Don't confuse reproducible chest wall/xiphoid tenderness with ongoing esophageal injury. Musculoskeletal pain from forceful vomiting is common and expected. The absence of subcutaneous air and her clinical improvement make esophageal perforation (Boerhaave syndrome) extremely unlikely.
Rebleeding, when it occurs, typically happens within 24 hours 7. Your patient is already 48 hours out and improving—her risk window has essentially passed.